DUBLIN, June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
Success by nearly all measures with Praxis Precision Medicines Inc.’s essential tremor phase III candidate, ulixacaltamide, drove the company’s stock up by more than 200% and provided supportive data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results